Bumetanide Pediatric Dose — Diuretics
Bumetanide is a potent loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, promoting rapid natriuresis and diuresis. It is used in pediatric patients for the management of fluid overload, edema associated with heart failure, renal disease, and hepatic dysfunction. Bumetanide is approximately 40 times more potent than furosemide on a milligram-per-milligram basis.
Pediatric Dosing
- Intermittent dosing (IV or PO): 0.01–0.05 mg/kg per dose
- Continuous infusion: 0.05 mg/kg/hr, titrated to clinical effect
Doses may be repeated or titrated based on diuretic response; consult institutional protocol for dosing frequency and maximum single dose guidance.
Worked example — 10 kg child (intermittent dosing):
Low end: 10 kg × 0.01 mg/kg = 0.1 mg per dose
High end: 10 kg × 0.05 mg/kg = 0.5 mg per dose
Continuous infusion: 10 kg × 0.05 mg/kg/hr = 0.5 mg/hr
Indications and Clinical Context
Bumetanide is indicated in pediatric patients requiring diuresis for conditions such as congestive heart failure, fluid overload in the PICU setting, nephrotic syndrome, and hepatic-associated edema. Its IV formulation is particularly valuable in critically ill patients with impaired enteral absorption or when rapid, reliable diuresis is needed. Continuous infusion is often preferred in the PICU when sustained, controlled diuresis is desired over intermittent bolus dosing, as it may provide more consistent urine output with potentially fewer electrolyte fluctuations.
Loop diuretics remain a cornerstone of fluid management in pediatric critical care. Selection of bumetanide over furosemide may be guided by its higher bioavailability when given orally and its potency advantage in refractory fluid overload, though both agents are acceptable per standard pediatric practice.
Administration and Monitoring
Bumetanide may be administered intravenously or orally (PO). IV bolus doses should be given slowly; consult institutional protocol for infusion rate guidance. For continuous infusions, initiate at 0.05 mg/kg/hr and titrate to the desired urine output. Monitor serum electrolytes — particularly potassium, sodium, and magnesium — closely during therapy, as hypokalemia and hypomagnesemia are common adverse effects. Blood pressure and renal function (BUN, creatinine) should also be monitored regularly.
- Monitor fluid balance, urine output, and daily weights
- Watch for ototoxicity, particularly with high doses or concurrent nephrotoxic/ototoxic agents
- Use with caution in patients with known sulfonamide hypersensitivity
- Electrolyte repletion may be required with prolonged or high-dose therapy
- Consult institutional protocol for maximum single dose and dosing interval
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.